Slide 1: Cipla
Cipla 22"d May, 2019 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 51h floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Sandra Kurla Complex, Sandra (East), Mumbai- 400 051 Scrip Code: 500087 S
Slide 2: Investor Presentation Q4FY19
Investor Presentation Q4FY19 22-05-2019
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Key highlights
Key highlights: 1 Expansion in 22.1% 75% 19.4% 12% EBITDA margins (Q4 EBITDA) Q4 EBITDA1 YoY Growth (FY19 EBITDA) FY19 EBITDA1 YoY Growth India South Africa 2 Continued growth across branded markets 11% 11.2% 12% 10.4% 3x (Q4 YoY Growth) As per IQVIA MAT FY19 Private Market As per IQVIA MAT Vs marke
Slide 5: FY19: Significant progress across our key priorities
FY19: Significant progress across our key priorities FY19 Growth US • Launch and ramp-up of differentiated products (gPulmicort, gVoltaren, gIsuprel,gSensipar) 18% FY19 Growth • Strong execution supported by prescription generation and market beating growth across key India therapies; in-licensed pr
Slide 6: Building a sustainable Specialty business: Inhaled itraconazole
Building a sustainable Specialty business: Inhaled itraconazole Marks Cipla’s entry into Specialty Respiratory segment Respiratory Specialty Pulmazole – Inhaled Itraconazole Cipla1 enters into a worldwide co-development and commercialization agreement of Pulmazole (PUR1900) – an inhaled iSPERSE™ for
Slide 7: Continued focus on maintaining balance sheet health with strong cash flow generation
Continued focus on maintaining balance sheet health with strong cash flow generation Net Debt Net Debt / Equity Net Debt / EBITDA1 22% 0.14 0.72 2,040 1,581 0.10 0.50 Mar'18 Mar'19 Mar'18 Mar'19 Mar'18 Mar'19 Capex optimization through a structured approach leading to improvement in cash flow gener
Slide 8: Financial Performance – Q4FY19
Financial Performance – Q4FY19 Revenues INR 4,404 Cr 19% EBITDA ~22.1% to sales ~700bps Q4 FY19 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q4 FY 18 (Rs Cr) 3% Europe, 5% 4% Total Revenue from 4,404 19% Operations India, 34% a) Domestic Sales 1,538 11% Emerging Mkts, 9% b) Int’l
Slide 9: Financial Performance – FY19
Financial Performance – FY19 Revenues INR 16,362 Cr 8% EBITDA 19.4% to sales ~80bps FY19 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs FY 18 (Rs Cr) 2% Europe, 4% 4% Total Revenue from 16,362 8% Operations a) Domestic Sales 6,367 6% Emerging India, 38% Mkts, 11% b) Int’l Sales 9,60
Slide 10: India (Rx + Gx) Sales: Strong growth momentum continues across key therapeutic areas
India (Rx + Gx) Sales: Strong growth momentum continues across key therapeutic areas Q4 Y-o-Y FY19 Y-o-Y Rs Cr Rs Cr 7000 1600 11% 1500 7% 6272 1353 6000 5867 Prescription Secondary Primary Impacted due to 1400 Growth Growth Growth channel 1200 5000 de-stocking 1000 4000 9% 11.2% 7% during the year
Slide 11: North America: Significant growth driven by ramp-up across key differentiated products
North America: Significant growth driven by ramp-up across key differentiated products Q4 Y-o-Y $ Mn Business-wise ramp-up (rounded-off) 163 116 41% $mn Cipla B2B Cipla DTM Invagen 287 Esomeprazole Invagen Acquisition Cinacalcet Strong growth 221 221 212 driven by differentiated assets 205 Q4 FY18 Q
Slide 12: ANDA Portfolio & Pipeline (As on 31st Mar 2019)
ANDA1 Portfolio & Pipeline (As on 31st Mar 2019) Total 164 24 65 253 ANDAs ANDA Portfolio 180 160 29 140 120 53 100 80 9 60 4 22 40 73 2 3 20 2 37 11 0 8 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs Cipla Ltd PEPFAR2 Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PE
Slide 13: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA*: South Africa, Sub-Saharan Africa and Cipla Global Access Q4 Y-o-Y FY19 Y-o-Y Q4: SA Private $ Mn $ Mn Market Local SA Private Market currency ZAR growth Local currency ZAR 30% 46 210 growth 149 (ex Animal Health; Inc Mirren) 45 12% (ex Animal Health; Inc Mirren) South Africa 33 19 124 106 Imp
Slide 14: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 70 61 40 30 -6% 58 33 25 60 35 25 50 30 21 18% 58% 20 40 25 21 30 20 15 15 10 20 10 10 5 5 0 0 0 Q4 FY18 Q4 FY19 Q4 FY18 Q4 FY19 Q4 FY18 Q4 FY19 Biosimilars franchise in the EM: Added Strong contribution from key accounts Strong ram
Slide 15: Priorities for FY20
Priorities for FY20 Continued growth across focused markets India US South Africa RoW & Others Above market growth Gx: Drive double digit Continue market leadership Strong growth in existing Continued strong private growth in key regions; franchises incl Respi + ramp- market performance Scale-up of
Slide 16: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q4FY19 15